- call +1-201-465-4211
- email sales@mrinsights.biz
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
Scope of the Report:
The worldwide market for Immune Checkpoint Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Immune Checkpoint Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
PD-1/PD-L1
CTLA-4
Market Segment by Applications, can be divided into
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
There are 15 Chapters to deeply display the global Immune Checkpoint Inhibitors market.
Chapter 1, to describe Immune Checkpoint Inhibitors Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Immune Checkpoint Inhibitors, with sales, revenue, and price of Immune Checkpoint Inhibitors, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Immune Checkpoint Inhibitors, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Immune Checkpoint Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Immune Checkpoint Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Immune Checkpoint Inhibitors Introduction
1.2 Market Analysis by Type
1.2.1 PD-1/PD-L1
1.2.2 CTLA-4
1.3 Market Analysis by Applications
1.3.1 Lung Cancer
1.3.2 Colorectal Cancer
1.3.3 Breast Cancer
1.3.4 Prostate Cancer
1.3.5 Melanoma
1.3.6 Blood Cancer
1.3.7 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bristol Myer Squibb
2.1.1 Business Overview
2.1.2 Immune Checkpoint Inhibitors Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca
2.2.1 Business Overview
2.2.2 Immune Checkpoint Inhibitors Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck & Co.
2.3.1 Business Overview
2.3.2 Immune Checkpoint Inhibitors Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Roche / Genentech
2.4.1 Business Overview
2.4.2 Immune Checkpoint Inhibitors Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Incyte Corporation
2.5.1 Business Overview
2.5.2 Immune Checkpoint Inhibitors Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 NewLink Genetics
2.6.1 Business Overview
2.6.2 Immune Checkpoint Inhibitors Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 ArGEN-X
2.7.1 Business Overview
2.7.2 Immune Checkpoint Inhibitors Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Seattle Genetics
2.8.1 Business Overview
2.8.2 Immune Checkpoint Inhibitors Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Pfizer
2.9.1 Business Overview
2.9.2 Immune Checkpoint Inhibitors Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 MacroGenics
2.10.1 Business Overview
2.10.2 Immune Checkpoint Inhibitors Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Celldex Therapeutics
2.11.1 Business Overview
2.11.2 Immune Checkpoint Inhibitors Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Celldex Therapeutics Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 CureTech
2.12.1 Business Overview
2.12.2 Immune Checkpoint Inhibitors Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 CureTech Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Immutep
2.13.1 Business Overview
2.13.2 Immune Checkpoint Inhibitors Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Immutep Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Innate Pharma
2.14.1 Business Overview
2.14.2 Immune Checkpoint Inhibitors Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Innate Pharma Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Sorrento Therapeutics
2.15.1 Business Overview
2.15.2 Immune Checkpoint Inhibitors Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 GlaxoSmithKline
2.16.1 Business Overview
2.16.2 Immune Checkpoint Inhibitors Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 GlaxoSmithKline Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 GITR, Inc
2.17.1 Business Overview
2.17.2 Immune Checkpoint Inhibitors Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 GITR, Inc Immune Checkpoint Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Immune Checkpoint Inhibitors Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Immune Checkpoint Inhibitors Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Immune Checkpoint Inhibitors Manufacturer Market Share in 2017
3.3.2 Top 6 Immune Checkpoint Inhibitors Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Immune Checkpoint Inhibitors Market Analysis by Regions
4.1 Global Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Regions
4.1.1 Global Immune Checkpoint Inhibitors Sales and Market Share by Regions (2013-2018)
4.1.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Regions (2013-2018)
4.2 North America Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
4.3 Europe Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
4.5 South America Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
5 North America Immune Checkpoint Inhibitors by Countries
5.1 North America Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Countries
5.1.1 North America Immune Checkpoint Inhibitors Sales and Market Share by Countries (2013-2018)
5.1.2 North America Immune Checkpoint Inhibitors Revenue and Market Share by Countries (2013-2018)
5.2 United States Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
5.3 Canada Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
5.4 Mexico Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
6 Europe Immune Checkpoint Inhibitors by Countries
6.1 Europe Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Countries
6.1.1 Europe Immune Checkpoint Inhibitors Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Immune Checkpoint Inhibitors Revenue and Market Share by Countries (2013-2018)
6.2 Germany Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
6.3 UK Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
6.4 France Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
6.5 Russia Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
6.6 Italy Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
7 Asia-Pacific Immune Checkpoint Inhibitors by Countries
7.1 Asia-Pacific Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Immune Checkpoint Inhibitors Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Immune Checkpoint Inhibitors Revenue and Market Share by Countries (2013-2018)
7.2 China Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
7.3 Japan Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
7.4 Korea Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
7.5 India Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
8 South America Immune Checkpoint Inhibitors by Countries
8.1 South America Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Countries
8.1.1 South America Immune Checkpoint Inhibitors Sales and Market Share by Countries (2013-2018)
8.1.2 South America Immune Checkpoint Inhibitors Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
8.3 Argentina Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
8.4 Colombia Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
9 Middle East and Africa Immune Checkpoint Inhibitors by Countries
9.1 Middle East and Africa Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Immune Checkpoint Inhibitors Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
9.3 UAE Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
9.4 Egypt Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
9.5 Nigeria Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
9.6 South Africa Immune Checkpoint Inhibitors Sales and Growth Rate (2013-2018)
10 Global Immune Checkpoint Inhibitors Market Segment by Type
10.1 Global Immune Checkpoint Inhibitors Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Immune Checkpoint Inhibitors Sales and Market Share by Type (2013-2018)
10.1.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Type (2013-2018)
10.2 PD-1/PD-L1 Sales Growth and Price
10.2.1 Global PD-1/PD-L1 Sales Growth (2013-2018)
10.2.2 Global PD-1/PD-L1 Price (2013-2018)
10.3 CTLA-4 Sales Growth and Price
10.3.1 Global CTLA-4 Sales Growth (2013-2018)
10.3.2 Global CTLA-4 Price (2013-2018)
11 Global Immune Checkpoint Inhibitors Market Segment by Application
11.1 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2013-2018)
11.2 Lung Cancer Sales Growth (2013-2018)
11.3 Colorectal Cancer Sales Growth (2013-2018)
11.4 Breast Cancer Sales Growth (2013-2018)
11.5 Prostate Cancer Sales Growth (2013-2018)
11.6 Melanoma Sales Growth (2013-2018)
11.7 Blood Cancer Sales Growth (2013-2018)
11.8 Other Sales Growth (2013-2018)
12 Immune Checkpoint Inhibitors Market Forecast (2018-2023)
12.1 Global Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate (2018-2023)
12.2 Immune Checkpoint Inhibitors Market Forecast by Regions (2018-2023)
12.2.1 North America Immune Checkpoint Inhibitors Market Forecast (2018-2023)
12.2.2 Europe Immune Checkpoint Inhibitors Market Forecast (2018-2023)
12.2.3 Asia-Pacific Immune Checkpoint Inhibitors Market Forecast (2018-2023)
12.2.4 South America Immune Checkpoint Inhibitors Market Forecast (2018-2023)
12.2.5 Middle East and Africa Immune Checkpoint Inhibitors Market Forecast (2018-2023)
12.3 Immune Checkpoint Inhibitors Market Forecast by Type (2018-2023)
12.3.1 Global Immune Checkpoint Inhibitors Sales Forecast by Type (2018-2023)
12.3.2 Global Immune Checkpoint Inhibitors Market Share Forecast by Type (2018-2023)
12.4 Immune Checkpoint Inhibitors Market Forecast by Application (2018-2023)
12.4.1 Global Immune Checkpoint Inhibitors Sales Forecast by Application (2018-2023)
12.4.2 Global Immune Checkpoint Inhibitors Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Immune Checkpoint Inhibitors Picture
Table Product Specifications of Immune Checkpoint Inhibitors
Figure Global Sales Market Share of Immune Checkpoint Inhibitors by
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
